
The infographic provides information about the clinical characteristics used to classify moderate COPD exacerbations and the impact of these events on lung function, future risk, and mortality.
Professor Matthias Augustin details the various clinical manifestations of prurigo nodularis, illustrating how different lesion types can present concurrently in patients.

Drs. Bob Geng and Lawrence Eichenfield highlight a multidisciplinary team approach to patient-centered care in diseases with type 2 inflammation

Explore the role of interleukin (IL)-33 in chronic obstructive pulmonary disease (COPD) pathophysiology and its potential as a therapeutic target.
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.

Join experts Henrik Watz, Mona Bafadhel, and Alberto Papi for an educational symposium on the link between underlying drivers of COPD with type 2 inflammation and cumulative patient burden, exploring the role of type 2 cytokines, and current and emerging therapies.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Brian Kim provides an overview of itch in type 2 inflammatory skin diseases and explains how the shared and unique mechanisms that drive inflammation and itch mediate each disease in distinct ways.

This full video presentation of the April 2025 WCPD symposium features Dr Amy Paller, Dr Paula Luna, and Dr Eulàlia Baselga. The faculty present the latest data on the possibility of achieving disease modification in infants and children with atopic dermatitis.
Explore the concept of disease modification in atopic dermatitis through this interactive infographic, which highlights potential considerations such as optimal sustained disease control, subclinical inflammation, the pathophysiology of AD, and atopic/non-atopic comorbidities.